Investigational drug · Phase 2
Efineptakin
Also called: NT-I7, rhIL-7-hyFc
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
36
Any phase or sponsor naming "Efineptakin"
First trial start
2020
Jun 10, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Efineptakin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Any Advanced Solid Tumors
- Triple Negative Breast Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Microsatellite Stable Colorectal Cancer
- Pancreatic Cancer
- Ovarian Cancer
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Colorectal cancer · Ovarian cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Efineptakin" as an intervention, largest first.
NeoImmuneTechIndustry
NCT04332653 · 215 participants · Start Jun 10, 2020 · Primary completion Nov 22, 2024
Drug: NT-I7; pembrolizumab (KEYTRUDA®) · For: Any Advanced Solid Tumors; Triple Negative Breast Cancer; Non Small Cell Lung Cancer and 4 more
Sites: Tampa, Florida; Detroit, Michigan; St Louis, Missouri · 8 sites in all
- A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19Pivotal-lookingStatus unknown
PT Kalbe Genexine BiologicsIndustry
NCT04810637 · 210 participants (planned) · Start Nov 1, 2020 · Primary completion Jun 2021
Drug: GX-I7 · For: Covid19
Sites: Jakarta Pusat, Indonesia · 2 sites in all
Genexine, Inc.Industry
NCT03752723 · 84 participants · Start Mar 27, 2019 · Primary completion May 11, 2023
Drug: GX-I7; Pembrolizumab(KEYTRUDA®) and 1 more · For: Triple Negative Breast Cancer
Sites: Seongnam-si, South Korea; Suwon, South Korea; Goyang-si, South Korea · 12 sites in all
- Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.Status unknown
SL VAXiGENIndustry
NCT06344715 · 78 participants (planned) · Start Oct 17, 2022 · Primary completion Oct 31, 2024
Drug: SL-T10; GX-I7 and 1 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sites: Seoul, South Korea
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05600920 · 60 participants (planned) · Start Nov 6, 2024 · Primary completion Nov 1, 2026
Drug: Recombinant human interleukin (IL) 7-hyFc · For: Idiopathic CD4 Lymphopenia
Sites: Bethesda, Maryland
- Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerActive, not recruiting
Yonsei UniversityAcademic, hospital or other
NCT05286060 · 56 participants (planned) · Start Mar 1, 2022 · Primary completion Oct 2026
Drug: GX-188E, GX-I7, Pembrolizumab; GX-188E, Pembrolizumab and 2 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Seoul, South Korea
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruiting
Mayo ClinicAcademic, hospital or other
NCT05465954 · 53 participants · Start Jan 24, 2023 · Primary completion Sep 2, 2026
Drug: Efineptakin alfa; Pembrolizumab · For: High Grade Astrocytic Tumor; Recurrent Glioblastoma, IDH-Wildtype; Recurrent Gliosarcoma
Sites: Rochester, Minnesota
Washington University School of MedicineAcademic, hospital or other
NCT07200089 · 52 participants (planned) · Start Jun 5, 2026 · Primary completion Mar 10, 2028
Drug: NT-I7; Placebo · For: Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
Sites: St Louis, Missouri
Seoul St. Mary's HospitalAcademic, hospital or other
NCT03206138 · 50 participants (planned) · Start May 30, 2017 · Primary completion Oct 2018
Drug: GX-188E, GX-I7; GX-188E, Imiquimod · For: Cervical Intraepithelial Neoplasia 3
Sites: Seoul, South Korea
National Cancer Institute (NCI)NIH
NCT00923351 · 44 participants · Start Jun 2, 2007 · Primary completion Aug 30, 2012
Drug: Tumor Purged/CD25 Depleted Lymphocytes; Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine and 2 more · For: Neuroblastoma; Sarcoma; Rhabdomyosarcoma-Embryonal and 2 more
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Efineptakin alfa (NT-I7) improves overall survival and induces immune niches in murine tumors.
Dinh T, Lee J, Islam S, et al. · Genes Dis 2027
- Exact Formula of the Total Quasi-Steady State Approximation in Competitive Target-Mediated Drug Disposition.
Kim T, Cha J, Jeon H, et al. · Comput Struct Biotechnol J 2026
- Long-acting IL-7 restores T-cell reconstitution in a humanized mouse model of lymphopenia.
Pérez-Díez A, Liu X, Bennett A, et al. · J Allergy Clin Immunol 2026
- NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.
Butt OH, Singhal K, Luo J, et al. · Clin Cancer Res 2026
- Long-acting IL-7 induces distinct transcriptomic features in peripheral T cells of patients with solid tumors.
Jang H, Kim JY, Kim S, et al. · JCI Insight 2026
- Expansion and mobilization of virus-specific stem-like CD8 T cells in chronic viral infection after treatment with a long-acting IL-7, NT-I7.
Lee J, Niavi C, Ahn E, et al. · Cell Rep 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.